Kalbe Farma Tbk Stock EBITDA
| KLBF Stock | IDR 1,485 20.00 1.37% |
Kalbe Farma Tbk fundamentals help investors to digest information that contributes to Kalbe Farma's financial success or failures. It also enables traders to predict the movement of Kalbe Stock. The fundamental analysis module provides a way to measure Kalbe Farma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kalbe Farma stock.
Kalbe |
Kalbe Farma Tbk Company EBITDA Analysis
Kalbe Farma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Kalbe Farma EBITDA | 4.54 T |
Most of Kalbe Farma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kalbe Farma Tbk is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Kalbe Farma Tbk reported earnings before interest,tax, depreciation and amortization of 4.54 T. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all Indonesia stocks is significantly lower than that of the firm.
Kalbe EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kalbe Farma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kalbe Farma could also be used in its relative valuation, which is a method of valuing Kalbe Farma by comparing valuation metrics of similar companies.Kalbe Farma is currently under evaluation in ebitda category among its peers.
Kalbe Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 95.3 T | |||
| Shares Outstanding | 46.26 B | |||
| Shares Owned By Insiders | 58.08 % | |||
| Shares Owned By Institutions | 15.23 % | |||
| Price To Book | 5.06 X | |||
| Price To Sales | 3.36 X | |||
| Revenue | 26.26 T | |||
| Gross Profit | 11.11 T | |||
| EBITDA | 4.54 T | |||
| Net Income | 3.18 T | |||
| Cash And Equivalents | 3.32 T | |||
| Total Debt | 532.51 B | |||
| Book Value Per Share | 420.94 X | |||
| Cash Flow From Operations | 2.83 T | |||
| Earnings Per Share | 72.54 X | |||
| Price To Earnings To Growth | 3.54 X | |||
| Target Price | 2345.0 | |||
| Number Of Employees | 12.64 K | |||
| Beta | 0.32 | |||
| Market Capitalization | 104.08 T | |||
| Total Asset | 25.67 T | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 25.67 T | |||
| Last Dividend Paid | 35.0 |
About Kalbe Farma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kalbe Farma Tbk's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kalbe Farma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kalbe Farma Tbk based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Kalbe Stock
Kalbe Farma financial ratios help investors to determine whether Kalbe Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kalbe with respect to the benefits of owning Kalbe Farma security.